Asenapine
Title: Asenapine
CAS Registry Number: 65576-45-6
CAS Name: (3aR,12bR)-rel-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
Molecular Formula: C17H16ClNO
Molecular Weight: 285.77
Percent Composition: C 71.45%, H 5.64%, Cl 12.41%, N 4.90%, O 5.60%
Literature References: Combined serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related to mianserin, q.v. Prepn: BE 854915 (1977 to Akzo); W. J. van der Burg, US 4145434 (1979 to Akzona). Synthesis of labelled compd: J. Vader et al., J. Labelled Compd. Radiopharm. 34, 845 (1994). Series of articles on properties, metabolism and pharmacology: Arzneim.-Forsch. 40, 536-554 (1990). Receptor binding study: E. Richelson, T. Souder, Life Sci. 68, 29 (2000). Clinical pharmacology: B. Andrée et al., Psychopharmacology 131, 339 (1997). Review of development and therapeutic potential: J. J. Miguel-Hidalgo, Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs 2, 85-92 (2000).
Properties: Log P at 37° (n-octanol/water): 6.33.
Log P: Log P at 37° (n-octanol/water): 6.33
 
Derivative Type: Maleate
CAS Registry Number: 85650-56-2
Manufacturers' Codes: Org-5222
Molecular Formula: C17H16ClNO.C4H4O4
Molecular Weight: 401.84
Percent Composition: C 62.77%, H 5.02%, Cl 8.82%, N 3.49%, O 19.91%
Properties: Racemic mixture. Crystals, mp 141-145°. uv max (ethanol): 270 nm (e 1900). Soly at 21° (g/l): water 3, ethanol 30, methanol 250, acetone 125, ethyl acetate 10, dichloromethane 250, hexane <1. pH at 20° (0.1% soln in water): 4.56 ±0.05. pH at 23° (saturated soln 5.8 g/l): 4.43. pK1 <3, pK2 7.52, pK3 8.51.
Melting point: mp 141-145°
pKa: pK1 <3, pK2 7.52, pK3 8.51
Absorption maximum: uv max (ethanol): 270 nm (e 1900)
 
Therap-Cat: Antipsychotic.
Keywords: Antipsychotic; Other Tricyclics; Serotonin-Dopamine Antagonist.

Others monographs:
Stearic AcidEtioporphyrino-Orsellinic Acid1H-Purine
Veratrine (Mixture)MethoxsalenGuanidinium Aluminum Sulfate HexahydrateHydrocortamate
EPTCSilver SubfluorideTiaramideSaralasin
ClidanacVanadyl SulfateBlebbistatinBucindolol
©2016 DrugLead US FDA&EMEA